Episode 819: Cardiol Therapeutics ($CRDL): A New Approach to Treating Inflammation in Heart Disease
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to wishlist failed.
Please try again later
Remove from wishlist failed.
Please try again later
Adding to library failed
Please try again
Follow podcast failed
Unfollow podcast failed
Episode 819: Cardiol Therapeutics ($CRDL): A New Approach to Treating Inflammation in Heart Disease
-
Narrated by:
-
By:
Summary
This interview is disseminated on behalf of Cardiol Therapeutics Inc.
In this episode of Stocks to Watch, we sit down with David Elsley, President and CEO of Cardiol Therapeutics (NASDAQ: CRDL | TSX: CRDL), to discuss the company's late-stage clinical development program targeting inflammation-driven heart conditions, including recurrent pericarditis and acute myocarditis.
Learn more: https://www.cardiolrx.com
Watch the full YouTube interview here: https://youtu.be/NXkzgfWHQnA
And follow us to stay updated: https://www.youtube.com/GlobalOneMedia
adbl_web_anon_alc_button_suppression_c
No reviews yet